References
- Lipner SR, Scher RK. Onychomycosis: clinical overview and diagnosis. J Am Acad Dermatol. 2019;80:835–851.
- Lipner SR, Scher RK. Onychomycosis: treatment and prevention of recurrence. J Am Acad Dermatol. 2019;80:853–867.
- Lipner SR. Pharmacotherapy for onychomycosis: new and emerging treatments. Expert Opin Pharmacother. 2019;20:725–735.
- Federal Drug Administration. 2019. Federal Drug Administration Adverse Event Reporting System [database]. Available from: https://fis.fda.gov/sense/app/d10be6bb-494e-4cd2-82e4-0135608ddc13/sheet/33a0f68e-845c-48e2-bc81-8141c6aaf772/state/analysis
- Google. 2019. Google Trend [database]. Available from: https://trends.google.com/trends/?geo=US
- LAMISIL (terbinafine hydrochloride) tablets [package insert]. East Hanover (NJ): Novartis Pharmaceuticals Corporation; [accessed 2019 Sep 25]. Available from: https://www.pharma.us.novartis.com/sites/www.pharma.us.novartis.com/files/Lamisil_tablets.pdf
- Beutler M, Hartmann K, Kuhn M, et al. Taste disorders and terbinafine. BMJ. 1993;307:26.
- Bong JL, Lucke TW, Evans CD. Persistent impairment of taste resulting from terbinafine. Br J Dermatol. 1998;139:747–748.
- Doty RL, Haxel BR. Objective assessment of terbinafine-induced taste loss. Laryngoscope. 2005;115:2035–2037.
- Stricker BHC, VAN Riemsdijk MM, Sturkenboom MCJM, et al. Taste loss to terbinafine: a case-control study of potential risk factors. Br J Clin Pharmacol. 2003;42:313–318.
- Faergemann J, Zehender H, Denouël J, et al. Levels of terbinafine in plasma, stratum corneum, dermis-epidermis (without stratum corneum), sebum, hair and nails during and after 250 mg terbinafine orally once per day for four weeks. Acta Derm Venereol. 1993;73:305–309.
- Granger EM, Glendinning JI, Smith JC, et al. Behavioral and electrophysiological responses to NaCl in young and old fischer-344 rats. Chem Senses. 1993;18:419–426.
- Gupta AK, Chang P, Del Rosso JQ, et al. Onychomycosis in children: prevalence and management. Pediatr Dermatol. 1998;15:464–471.
- Gupta AK, Mays RR, Versteeg SG, et al. Onychomycosis in children: safety and efficacy of antifungal agents. Pediatr Dermatol. 2018;35:552–559.
- Patel D, Castelo-Soccio LA, Rubin AI, et al. Laboratory monitoring during systemic terbinafine therapy for pediatric onychomycosis. JAMA Dermatol. 2017;153:1326–1327.
- Walmart, Inc. Retail prescription program drug list; 2019 [accessed 2019 Oct 2]. Available from: https://www.goodrx.com/spironolactone?label_override=spironolactone&form=tablet&dosage=100mg&quantity=30
- Centers for Medicare & Medicaid Services. Clinical laboratory fee schedule. 2019 [accessed 2019 Oct 2]. Available from: https://www.cms.gov/apps/ama/license.asp?file=/Medicare/Medicare-Fee-for-Service-Payment/ClinicalLabFeeSched/Downloads/19CLABQ1.zip
- Centers for Medicare & Medicaid Services. Medicare provider utilization and payment data. 2017 [accessed 2019 Oct 2]. Available from: https://data.cms.gov/Medicare-Physician-Supplier/Medicare-Provider-Utilization-and-Payment-Data-Phy/fs4p-t5eq/data
- Stolmeier DA, Stratman HB, McIntee TJ, et al. Utility of laboratory test result monitoring in patients taking oral terbinafine or griseofulvin for dermatophyte infections. JAMA Dermatol. 2018;154:1409–1416.
- Lazaros GA, Papatheodoridis GV, Delladetsima JK, et al. Terbinafine-induced cholestatic liver disease. J Hepatol. 1996;24:753–756.
- Food and Drug Administration. Aldactone SPORANOX® (itraconazole) Capsules. Physician Labeling. [accessed 2019 Oct 2]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020083s040s041s044lbl.pdf
- Food and Drug Administration. DIFLUCAN® (fluconazole) Tablets. Physician Labeling. [accessed 2019 Oct 2]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/019949s051lbl.pdf
- Food and Drug Administration. Jublia (efinaconazole) approval date. [accessed 2019 Oct 2]. Available from: https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshot-jublia-efinaconazole
- Sinclair N. 2016. Tv Ad Revenue Rising Pharmaceuticals Drugs. Available from: https://finance.yahoo.com/news/tv-ad-revenue-rising-pharmaceuticals-drugs-175632922.html